PharmaShots’ Post

Roche to Present Data from the P-III (OCARINA II) Clinical Evaluation of Ocrevus to Treat Progressive and Relapsing Multiple Sclerosis #roche #ocrevus #multiplesclerosis #clinicaltrial #phase3 #treatment #safety #efficacy #progressive #relapse #pharmacokinetics #usfda #ema #ocarina2

Evidence for the feasibility, early efficacy and safety of incorporating comprehensive #GenomicProfiling into clinical practice to provide #personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at #ESMO24. DLCTs explore the effects of #biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of #PrecisionOncology in large patient numbers, according to Vivek Subbiah, MD. 👇Read the full article on the #ESMODailyReporter https://ow.ly/tVNg50ToglA

If we are really looking into these precision medicine initiatives- what we are doing right now is fishing for those patients who have a chance to respond to immune therapy and make sure they get it. As for the rest, it's stable disease and the hope for the occasional responder and gratefulness for any life saved. So basically, it's super-easy to be snarky and criticise and lament we should have just *prevented it all*. The kicker is this- this is the worst-off cancer patient population there is. Those who have been through all lines of treatment- and the cohorts are full of those cancers with no good treatments to start with. These are the people who are usually sent off to some more or less reasonable Ph1- or directly to palliative care to hopefully die at least without being in pain. This is the stage of disease that gives cancer its bad reputation and causes the fear- it makes it the Voldemort where people only talk about the 'c-word'. After having been through this with my husband and having become a person where people go when there's nothing left- I think it's down to 2 things: 1. we aren't particularly good at dealing with our own mortality in general and working close to death gives you a lot of pause for thought. 2. it's a clear demonstration of what we have not understood and cannot control in medicine and that's a particularly tough one when you are a clinician or a cancer researcher. And yes, we should prevent whatever is possible. But we cannot prevent everything. And we cannot undo the past- what we see now is the outcomes of prevention gone wrong for decades. And with age being one of the biggest risk factors for cancer, ageing societies don't have a good way out anyway. So the real question is whether we have the guts to tackle a setting with very little happy survivor stories. Or whether we somehow deep down think that we just aren't smart enough to crack this.

Impact of SC Daratumumab: Panelists discuss how the FDA approval of daratumumab and hyaluronidase-fihj combined with VRd (bortezomib, lenalidomide, and dexamethasone) for induction and consolidation in transplant-eligible newly diagnosed multiple myeloma patients is changing treatment approaches while also considering how recent evidence suggesting reduced observation time for subcutaneous (SC) daratumumab administration may streamline patient care and improve treatment efficiency. #finance #pharmacy #lifesciences

A recent study by Christopher Willy Schwarz and colleagues presented at #EADV24 reveals insight into 𝐧𝐨𝐧-𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐬𝐰𝐢𝐭𝐜𝐡𝐞𝐬 between adalimumab products in patients with psoriasis. ✅ The risk of discontinuation was 0-8% within six months among 180 patients undergoing non-medical switches. 💉 The highest discontinuation rate was found for patients switching from the reference to a biosimilar drug. 🌍 The results are comparable with previous studies, thus adding to the growing evidence of the safety of adalimumab switches. 📸 Hear more about the exciting results at Dermatologi DK: https://lnkd.in/dcccBnu7

In an interview with The Clinical Trial Vanguard’s Moe Alsumidaie, Elysium Therapeutics, Inc. CEO Greg Sturmer discusses O2P, a groundbreaking path to #painrelief that’s designed to help reduce the risk of opioid misuse. #opioidoverdose #opioidepidemic #painmedication #opioidmisuse #elysiumtherapeutics #hydrocodone https://lnkd.in/eUnapmfJ

Is screening of patients for Pseudomonas aeruginosa groin/rectal carriage useful in identifying those at risk of bacteraemia in haematology and other high-risk clinical settings? https://lnkd.in/eJecUrht

Are you a myositis patient with ILD? Have you wanted to participate in a clinical trial from the comfort of your own home? The MINT clinical trial is for patients with ILD (pulmonary fibrosis) associated with myositis. The goal of this study is to gain a better understanding of how anti-fibrotic drugs can help treat myositis associated with ILD. The study will focus on the drug Nintedanib (brand name Ofev), an oral anti-fibrotic medication approved by the Food and Drug Administration (FDA) for the treatment of various types of ILD This clinical trial is unique as you can participate from the comfort of your own home. There is no need, or worry, about traveling long distances or spending time away from your surroundings. To inquire and find out if you're eligible, please contact Dr. Rohit Aggarwal, medical director of Arthritis and Autoimmunity Center at University of Pittsburgh Medical Center To inquire please email; MINTcc@pitt.edu or call #412-648-4005 #ClinicalTrial #MINTStudy #ILD #Myositis #InterstitialLungDisease #LungDisease #MyositisStudy #ILDStudy #MINTtrial #MyositisPatients

TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

As the landscape of hematological malignancies dramatically changes due to diagnostic and therapeutic advances, it is important to evaluate trends in clinical trial designs. The objective of this study was to describe the design of clinical trials for five common hematological malignancies with respect to randomization and endpoints. It also aimed to assess trends over time and examine the relationships of funding source and country of origin to proportions of randomization and utilization of clinical endpoints. Learn more: